Safety review of second dose-level cohort allows study to advance to third cohort of colorectal…
Continue Reading-
Galecto Announces Pricing of Initial Public Offering
BOSTON and COPENHAGEN, Denmark, Oct. 28, 2020 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a…
Continue Reading -
Neuro Event Labs Receives FDA Breakthrough Device Designation for Nelli®
SAN ANTONIO (PRWEB) OCTOBER 22, 2020 Neuro Event Labs, Inc., a global diagnostic company, announced that…
Continue Reading -
Abliva doses the first patient in its KL1333 Phase Ia/b clinical study
Abliva AB (Nasdaq Stockholm: ABLI) today announced that the first primary mitochondrial disease patient in…
Continue Reading -
GALECTO
Galecto is a Danish drug development company based in Copenhagen...
Continue Reading -
Hadean Ventures invest in Galecto`s $64 million round equity financing
Funds will support preparations for potential EU conditional approval of GB0139 in IPF and multiple…
Continue Reading -
Ingrid Teigland Akay included in Business Insider’s list of 100 People Transforming Business in Europe.
Ingrid Teigland Akay Managing Partner, Hadean Ventures There’s a growing desire among investors not only…
Continue Reading -
Abliva intends to start a pivotal KL1333 study second half 2021
Abliva AB (Nasdaq Stockholm: ABLI) today announced that the company’s Board of Directors has decided…
Continue Reading -
Oncoinvent Advances Radspherin[®] to Second Dose Level in Ongoing Phase 1 Clinical Trial
FRI, SEP 04, 2020 09:19 CET Safety review of first dose-level cohort allows progression to…
Continue Reading
